Literature DB >> 10424636

Determining costs of health care services for cost-effectiveness analyses: the case of cervical cancer prevention and treatment.

L J Helms1, J Melnikow.   

Abstract

OBJECTIVES: To estimate costs for the prevention and treatment of cervical cancer based on resource utilization and to compare those costs to published estimates and to local charges and reimbursements.
DESIGN: Cost estimates for cervical cancer prevention services were based on clinic staff time, use of specialized equipment and supplies, laboratory costs, and clinic overhead. Cost estimates for cervical cancer treatment were based on HMO expenditures for cervical cancer patients and control patients. These costs were adjusted for stage distribution and survival rates. Published cost estimates were obtained from a systematic review of the medical literature between 1990 and 1996.
SETTING: Three family planning clinics (for prevention costs) and a staff-model HMO (for treatment costs). PATIENTS: For treatment costs: 98 cervical cancer patients and 133,058 female control patients, matched by age and chronic disease score. MAIN OUTCOME MEASURES: Estimated costs for prevention and treatment of cervical cancer. Cost-to-charge and cost-to-reimbursement ratios.
RESULTS: Costs of cervical cancer prevention and treatment services have been determined using a variety of methods. We found substantial variation in these estimates, even for studies with similar methodologies. Detailed resource-based estimation suggests that prevention costs are generally lower than those previously published in the literature, whereas the costs of cervical cancer treatment are generally higher.
CONCLUSIONS: It is practical and desirable to employ resource use-based estimates of medical costs in cost-effectiveness analyses. Failure to do so for cervical cancer may affect policy recommendations by understating the relative benefits of prevention programs.

Entities:  

Mesh:

Year:  1999        PMID: 10424636     DOI: 10.1097/00005650-199907000-00005

Source DB:  PubMed          Journal:  Med Care        ISSN: 0025-7079            Impact factor:   2.983


  6 in total

1.  Accuracy and cost-effectiveness of cervical cancer screening by high-risk human papillomavirus DNA testing of self-collected vaginal samples.

Authors:  Akhila Balasubramanian; Shalini L Kulasingam; Atar Baer; James P Hughes; Evan R Myers; Constance Mao; Nancy B Kiviat; Laura A Koutsky
Journal:  J Low Genit Tract Dis       Date:  2010-07       Impact factor: 1.925

2.  Cost and resource utilization in cervical cancer management: a real-world retrospective cost analysis.

Authors:  I Cromwell; Z Ferreira; L Smith; K van der Hoek; G Ogilvie; A Coldman; S J Peacock
Journal:  Curr Oncol       Date:  2016-02-29       Impact factor: 3.677

Review 3.  Assessing the annual economic burden of preventing and treating anogenital human papillomavirus-related disease in the US: analytic framework and review of the literature.

Authors:  Ralph P Insinga; Erik J Dasbach; Elamin H Elbasha
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

4.  Options for managing low grade cervical abnormalities detected at screening: cost effectiveness study.

Authors: 
Journal:  BMJ       Date:  2009-07-28

5.  Cost-effectiveness of a potential vaccine for human papillomavirus.

Authors:  Gillian D Sanders; Al V Taira
Journal:  Emerg Infect Dis       Date:  2003-01       Impact factor: 6.883

6.  Cost savings associated with improving appropriate and reducing inappropriate preventive care: cost-consequences analysis.

Authors:  William Hogg; Neill Baskerville; Jacques Lemelin
Journal:  BMC Health Serv Res       Date:  2005-03-09       Impact factor: 2.655

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.